Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

$7 Billion Amylin Buyout Boosts BMS, AZ Diabetes Partnership

Jun 30 2012

• By Chris Morrison

Related Content

AstraZeneca Takes Out Antibiotic Firm Novexel, With Cash Back from Forest

Dec 23 2009

Amylin, Lilly End Exenatide Tie-Up, Marking End To Litigation

Nov 08 2011

Weeks After <em>Bydureon</em> Launch, Amylin Looks Like A Takeout Target

Mar 29 2012

Dapagliflozin Faces Ominous Prospect Of New Trials

Jan 19 2012

Diabetes Leaders Lilly, Sanofi Give A Glimpse Of GLP-1 Strategy

Jun 14 2012

BMS Deals Diabetes Drugs, Solidifies Specialist Stance

Feb 01 2007

Related Companies

Bristol Myers Squibb Company

Bristol Myers Squibb Company

AstraZeneca PLC

Eli Lilly and Company

Novo Nordisk A/S

GSK plc

Sanofi

Takeda Pharmaceutical Co. Ltd.

Forest Laboratories, Inc.

Additional Topics

Business Strategies Deals BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window